GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Return-on-Tangible-Asset

Changzhou Qianhong Biopharma Co (SZSE:002550) Return-on-Tangible-Asset : 16.33% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Changzhou Qianhong Biopharma Co's annualized Net Income for the quarter that ended in Mar. 2024 was ¥416 Mil. Changzhou Qianhong Biopharma Co's average total tangible assets for the quarter that ended in Mar. 2024 was ¥2,550 Mil. Therefore, Changzhou Qianhong Biopharma Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 16.33%.

The historical rank and industry rank for Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:002550' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -5.16   Med: 7.82   Max: 12.88
Current: 7.49

During the past 13 years, Changzhou Qianhong Biopharma Co's highest Return-on-Tangible-Asset was 12.88%. The lowest was -5.16%. And the median was 7.82%.

SZSE:002550's Return-on-Tangible-Asset is ranked better than
73.87% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.83 vs SZSE:002550: 7.49

Changzhou Qianhong Biopharma Co Return-on-Tangible-Asset Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Return-on-Tangible-Asset Chart

Changzhou Qianhong Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.99 -5.16 7.74 12.88 6.96

Changzhou Qianhong Biopharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.34 4.66 11.80 -2.48 16.33

Competitive Comparison of Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset falls into.



Changzhou Qianhong Biopharma Co Return-on-Tangible-Asset Calculation

Changzhou Qianhong Biopharma Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=181.861/( (2656.27+2571.645)/ 2 )
=181.861/2613.9575
=6.96 %

Changzhou Qianhong Biopharma Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=416.432/( (2571.645+2528.926)/ 2 )
=416.432/2550.2855
=16.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Changzhou Qianhong Biopharma Co  (SZSE:002550) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Changzhou Qianhong Biopharma Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Changzhou Qianhong Biopharma Co (SZSE:002550) Business Description

Traded in Other Exchanges
N/A
Address
Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.

Changzhou Qianhong Biopharma Co (SZSE:002550) Headlines

No Headlines